Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Immunoprecise Antibodies Ltd IPA

ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. It has several subsidiaries in North America and Europe including entities, such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the IPA Family). Its Contract Research Organizations (CRO) services include B cell Select; Phage Display; DeepDisplay; Abthena Bispecifics; LucinaTech Humanization; Affinity Maturation; Immunization, hybridoma, sequencing; rPEx protein manufacturing, and Cell line development. The Company utilizes custom antigen modeling, target analysis using Natural Language Processing and the HYFTTM analysis to lay the groundwork for the subsequent experimental phases.


NDAQ:IPA - Post by User

Post by mercedesmanon Jul 22, 2021 11:40am
224 Views
Post# 33587809

Congrats to patient IPA longs...

Congrats to patient IPA longs...It's been a long, arduous 6 months post Nasdaq listing period.

The volume on the US side is incredible.  more than double the entire o/s share volume in just two hours of trading.  More coming.

Rumours of a deal with a Major will propel this further.

When (not if) that comes, watch out.

They have many more poly-trope concoctions in the works.  This pandemic will evolve into an endemic, that will establish the need for new innovative antibody therapies/vaccines/boosters to battle against constantly emerging variants.  Think beyond the ability to better deal with Delta (which in itself is great news).

Anyway...I love this company for it's potential to do good and make money for it's shareholders.

MM
<< Previous
Bullboard Posts
Next >>